Analyst Price Target is $2.00
▼ -2.44% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for AIM ImmunoTech in the last 3 months. The average price target is $2.00, with a high forecast of $2.00 and a low forecast of $2.00. The average price target represents a -2.44% upside from the last price of $2.05.
Current Consensus is
The current consensus among 1 polled investment analysts is to buy stock in AIM ImmunoTech.
AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Ocala, FL.